PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
about
The α-melanocyte stimulating hormone/peroxisome proliferator activated receptor-γ pathway down-regulates proliferation in melanoma cell lines.Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor.Research Advances in the Correlation between Peroxisome Proliferator-Activated Receptor-γ and Digestive Cancers.Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-N-(hydroxyl-<κ>O)benzamidato-<κ>O]dibutylitin(IV) with Human Peroxisome Proliferator-Activated Receptor hPPARγ.
P2860
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
@en
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
@nl
type
label
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
@en
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
@nl
prefLabel
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
@en
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
@nl
P2093
P2860
P356
P1476
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
@en
P2093
Maria Bellomo
Maria Luisa Nicolosi
Roberta Malaguarnera
Stefania Giuliano
P2860
P356
10.3389/FENDO.2017.00031
P577
2017-02-22T00:00:00Z